Annexon ANNX Stock
Annexon Price Chart
Annexon ANNX Financial and Trading Overview
| Annexon stock price | 4.72 USD |
| Previous Close | 2.93 USD |
| Open | 2.96 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 800 |
| Day's Range | 2.8 - 3.03 USD |
| 52 Week Range | 2.07 - 7.65 USD |
| Volume | 378.53K USD |
| Avg. Volume | 864.84K USD |
| Market Cap | 149.17M USD |
| Beta (5Y Monthly) | 0.470865 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.77 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.92 USD |
ANNX Valuation Measures
| Enterprise Value | -46489108 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.3192487 |
| PEG Ratio (5 yr expected) | -0.03 |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.69417 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.311 |
Trading Information
Annexon Stock Price History
| Beta (5Y Monthly) | 0.470865 |
| 52-Week Change | -6.33% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.65 USD |
| 52 Week Low | 2.07 USD |
| 50-Day Moving Average | 4.58 USD |
| 200-Day Moving Average | 5.32 USD |
ANNX Share Statistics
| Avg. Volume (3 month) | 864.84K USD |
| Avg. Daily Volume (10-Days) | 1.15M USD |
| Shares Outstanding | 53.08M |
| Float | 29.78M |
| Short Ratio | 1.56 |
| % Held by Insiders | 2.20% |
| % Held by Institutions | 100.70% |
| Shares Short | 2.17M |
| Short % of Float | 4.82% |
| Short % of Shares Outstanding | 4.09% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -36.44% |
| Return on Equity (ttm) | -69.92% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -149291008 USD |
| Net Income Avi to Common (ttm) | -145250000 USD |
| Diluted EPS (ttm) | -1.98 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 228.16M USD |
| Total Cash Per Share (mrq) | 4.3 USD |
| Total Debt (mrq) | 32.51M USD |
| Total Debt/Equity (mrq) | 15.13 USD |
| Current Ratio (mrq) | 10.136 |
| Book Value Per Share (mrq) | 4.048 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -119014000 USD |
| Levered Free Cash Flow (ttm) | -69235376 USD |
Profile of Annexon
| Country | United States |
| State | CA |
| City | Brisbane |
| Address | 1400 Sierra Point Parkway |
| ZIP | 94005 |
| Phone | 650 822 5500 |
| Website | https://www.annexonbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 80 |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Q&A For Annexon Stock
What is a current ANNX stock price?
Annexon ANNX stock price today per share is 4.72 USD.
How to purchase Annexon stock?
You can buy ANNX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Annexon?
The stock symbol or ticker of Annexon is ANNX.
Which industry does the Annexon company belong to?
The Annexon industry is Biotechnology.
How many shares does Annexon have in circulation?
The max supply of Annexon shares is 114.06M.
What is Annexon Price to Earnings Ratio (PE Ratio)?
Annexon PE Ratio is now.
What was Annexon earnings per share over the trailing 12 months (TTM)?
Annexon EPS is -1.77 USD over the trailing 12 months.
Which sector does the Annexon company belong to?
The Annexon sector is Healthcare.
Annexon ANNX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}